Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivdak post-marketing surveillance in advanced or recurrent cervical cancer with focus on ocular adverse events
jRCT2031250345Recruiting
- Sponsor
- Genmab
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tisotumab vedotin in Cervical Cancer (CC) (2 arms), sponsored by Genmab. Primary endpoint: Incidence and risk ratio of ocular disorders. Started Dec 2025; status: recruiting.
02
Drugs
tisotumab vedotin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2031250345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250345.